laitimes

China Biopharmaceuticals: The company's oncology product "Sunitinib Malate Capsules" obtained the drug registration certificate

China Biopharmaceutical Co., Ltd. announced that the group's key product in the field of oncology, "Shunitinib Malate Capsules" (trade name: Qingnishu) (approved specification: 12.5mg), has been issued a drug registration certificate by the State Drug Administration.

Read on